Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …

The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …

RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or
bacterial infection and induce host innate immune responses. The RLRs family comprises …

The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of
rarer CNS tumour types exists. The classification of these tumours is increasingly based on …

Glioblastoma (GBM) is the most aggressive form of primary brain tumor, for which effective
therapies are urgently needed. Cancer cells are capable of evading clearance by …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …

Gliomas are the most prevalent primary malignant brain tumors worldwide, with
glioblastoma (GBM) being the most common and aggressive type. Despite two decades of …

Spatial resolution of the T cell repertoire is essential for deciphering cancer-associated
immune dysfunction. Current spatially resolved transcriptomic technologies are unable to …

Abstract Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics
combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have …